All In Biotech

BLA 125326 · Novartis

Kesimpta

Ofatumumab · Subcutaneous, Injection · CD20-directed Cytolytic Antibody

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Oct 26, 2009

Approved uses

5

Original approval plus efficacy supplements

Registered trials

138

29 Phase 3, 12 recruiting

FAERS reports

33,639

14,965 serious, 779 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. KESIMPTA is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The precise mechanism by which ofatumumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ofatumumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 20, 2020 Supplement 70 · Efficacy · priority review LabelLetterReview
  • Aug 30, 2016 Supplement 63 · Efficacy · priority review OrphanLetterLabel
  • Jan 19, 2016 Supplement 62 · Efficacy · priority review LabelLetter
  • Apr 17, 2014 Supplement 60 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Oct 26, 2009 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanReviewSummary ReviewLabel
2 products under this application
  • KESIMPTA · OFATUMUMAB 20MG/0.4ML · SOLUTION, SUBCUTANEOUS · Prescription
  • ARZERRA · OFATUMUMAB 100MG/5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ofatumumab" as an intervention, any sponsor and status, largest first.

All 138 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue5,591
  • headache4,670
  • pyrexia3,632
  • pain3,599
  • chills3,506
  • influenza like illness2,934
  • nausea1,832
  • multiple sclerosis relapse1,741
  • covid-191,523
  • asthenia1,520
  • multiple sclerosis1,516
  • gait disturbance1,441

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20082
200910
2010102
2011151
2012235
2013285
2014275
2015328
2016232
2017155
2018162
2019109
2020680
20214,664
20227,299
20238,730
20244,695
20253,618
20261,907

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 175 on PubMed

Sponsor: Novartis · Also marketed as Arzerra

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.